Background: The era of multidrug-resistant (MDR) Gram-negative bacilli (GNB) has renewed interest in fosfomycin.
Aim: The present study evaluated the in vitro activity of fosfomycin against MDR urinary and nonurinary GNB isolates.
Materials and Methods: Fosfomycin susceptibility was carried out by agar dilution for a total of 279 (142 from urine and 137 from other samples) MDR-GNB. Disk diffusion was done for urinary isolates only.
Results: Urinary tract isolates had a high degree of susceptibility to fosfomycin (overall susceptibility, 90.8%), whereas only 42.9% of nonurinary isolates retained susceptibility to the drug. Percentage susceptibility rates for urinary and nonurinary isolates of Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter spp. were 99%, 91.3%, 66%, 0% and 62%, 44.4%, 32%, 11%, respectively.
Conclusion: Fosfomycin showed excellent in vitro activity for uropathogens. Large-scale evaluation of fosfomycin against MDR systemic isolates is required to evaluate its therapeutic efficacy.
Raz R. Fosfomycin: An old – New antibiotic. Clin Microbiol Infect 2012;18:4-7.
Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the infectious diseases society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011;52:e103-20.
Chitra C, Kumar D, Shakti L, Diana SR, Balaji V. Technical and interpretative issues of fosfomycin susceptibility testing. Indian J Med Microbiol 2015;33:611-2.
Clinical and Laboratory Standards Institute (CLSI). CLSI document M100S. Performance Standards for Antimicrobial Susceptibility testing – Twenty-Seventh Informational Supplement. Wayne: Clinical Laboratory Standards Institute (CLSI); 2017.
The European Committee on Antimicrobial Susceptibility Testing. Breakpoint Tables for Interpretation of MICs and Zone diameters. Version 7.0. Available from: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_7.0_Breakpoint_Tables.pdf. [Last accessed on 2017 Jun 01].
Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268-81.
Saiprasad PV, Krishnaprasad K. Exploring the hidden potential of fosfomycin for the fight against severe gram-negative infections. Indian J Med Microbiol 2016;34:416-20.
Banerjee S, Sengupta M, Sarker TK. Fosfomycin susceptibility among multidrug-resistant, extended-spectrum beta-lactamase-producing, carbapenem-resistant uropathogens. Indian J Urol 2017;33:149-54.
Perdigão-Neto LV, Oliveira MS, Rizek CF, Carrilho CM, Costa SF, Levin AS, et al. Susceptibility of multiresistant gram-negative bacteria to fosfomycin and performance of different susceptibility testing methods. Antimicrob Agents Chemother 2014;58:1763-7.